Rare Kidney Disease Market Size Worth over USD 12 Billion in 2035 | Roots Analysis

Owing to the positive clinical trial results, the rare kidney disease market is receiving significant investments from various stakeholders in the rare kidney disorders domain.

Considering the rising prevalence of rare kidney disorders and the ongoing research initiatives to develop novel and efficacious treatments, the rare kidney diseases market is likely to evolve at a healthy pace, over the next decade.

According to Roots Analysis, the rare kidney disease market is anticipated to be worth USD 2.8 billion in 2025, and this value is likely to reach over USD 11.6 billion by 2035, expanding at a CAGR of 15.2%.

Key Report Takeaways

• Currently, more than 165 rare kidney disease therapies are currently being evaluated across various stages of development; close to 70% of the rare kidney therapies are in clinical phase of development
• Presently, more than 110 companies are involved in the development rare kidney disease therapies are available across the world; majority of the companies are based in North America
• A comprehensive set of company profiles of prominent / emerging players offers valuable insights into their current strategic focus and future initiatives, empowering stakeholders with crucial information
• Since 2019, more than 75 deals have been inked by rare kidney disease developers; most of the collaborations were inked for the signed for the development of drugs targeting lupus nephritis
• Foreseeing lucrative returns, several strategic investors and venture capital firms have made investments, amounting to USD 7.9 billion, across more than 55 funding instances in the past five years
• Since 2019, more than 210 clinical trials have been registered for rare kidney disease therapies and a significant proportion of these trials are currently recruiting potential candidates for evaluating these novel therapeutics
• Pertaining to the rising incidence of chronic kidney diseases and the need for effective kidney disease management, we expect the rare kidney disease market to grow at an annualized rate of over 11% in the coming decade
• The anticipated future opportunity, in terms of annual service revenues, is expected to be well distributed across segments, such as target disease indication, type of molecule, type of biologics, route of administration, type of therapy and key geographical regions

Competitive Landscape of Rare Kidney Disease Market

The rare kidney disease landscape features over 165 rare kidney disease therapies being evaluated at various stages of development. Overall, the rare kidney disease market is highly fragmented, featuring the presence of established companies, as well as emerging start-ups and mid-sized companies.

It is interesting to highlight that most of the rare kidney disease developers are based in North America (52%), followed by those headquartered in Europe (23%). In addition to this, therapies targeting Lupus Nephritis dominate the rare kidney disorders drug pipeline.

Rare Kidney Disease Market Regional Outlook

Based on the key geographical regions, the rare kidney disease market can be segmented into four major regions, North America, Europe, Asia-Pacific and rest of the world. Led by the US, North America is anticipated to capture the majority of the rare kidney disease market in 2024.

Key industry players such as Novartis, Alexion Pharmaceuticals and Roche are pivotal in shaping the market dynamics. Additionally, the integration of scalable platforms is likely to be the reason to improve the manufacturing and development of rare kidney disease drugs in the region.

The Asia-Pacific is accounted to be the fastest-growing segment of the market. The growth of the rare kidney disease market in the region is driven by the rising prevalence of rare kidney disorders and the ongoing research initiatives to develop novel and efficacious treatments.

Rare Kidney Disease Market Key Players

Examples of key companies engaged in rare kidney disease market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Alexion Pharmaceuticals, Chinook Therapeutics, Horizon Therapeutics, Jiangsu Hengrui Pharmaceuticals, Novartis, Omeros, Roche, Sanofi, Travere Therapeutics, ZyVersa Therapeutics, Advicenne, Apellis Pharmaceuticals, argenx, Astellas Pharma, Boehringer Ingelheim, Calliditas Therapeutics, GSK, Mallinckrodt Pharmaceuticals, Synlogic, Takeda.

It is interesting to note that in May 2023, Chinook Therapeutics entered into product development and commercialization agreement with Ionis Pharmaceuticals, in order to develop antisense therapy for rare kidney diseases. Such types of agreements are expected to drive the market of rare kidney diseases.

Rare Kidney Disease Market Segments

Based on research, Roots Analysis has segmented the Rare Kidney Disease Market into Type of Target Disease Indication, Type of Molecule, Type of Biologic, Route of Administration, Type of Therapy, Key Geographical Regions and Leading Drug Developers.

Distribution by Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Fabry Disease, Immunoglobulin A Nephropathy, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney Disease, Lupus Nephritis and Others), Type of Molecule (Small Molecules and Biologics), Type of Biologics (Monoclonal Antibody, Hormone, Recombinant Protein, and Others), Route of Administration (Oral, Intravenous, Subcutaneous, and Others), Type of Therapy (Monotherapy and Combination Therapy) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World

by Type of Target Disease Indications

• Atypical Hemolytic Uremic Syndrome
• Fabry Disease
• Immunoglobulin A Nephropathy
• Focal Segmental Glomerulosclerosis
• Autosomal Dominant Polycystic Kidney Disease
• Lupus Nephritis
• Others

by Type of Molecule

• Small Molecules
• Biologics

by Type of Biologics

• Monoclonal Antibodies
• Proteins

by Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Others

by Type of Therapy

• Monotherapy
• Combination Therapy

by Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the subject given. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact US

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Email: sales@rootsanalysis.com